A Bortezomib-based Regimen Offers Promising Survival and Graft-vs.-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial

Hematopoietic stem cell transplantation (HSCT) recipients lacking HLA-matched related donors have increased graft-vs.-host disease (GVHD) and non-relapse mortality (NRM). Bortezomib added to reduced-intensity conditioning can offer benefit in T-replete HLA-mismatched HSCT, and may also benefit myelo...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Biol Blood Marrow Transplant
Autores principales: Koreth, John, Kim, Haesook T., Lange, Paulina B., Bindra, Bhavjot, Reynolds, Carol G., Chammas, Marie J., Armand, Philippe, Cutler, Corey S., Ho, Vincent T., Glotzbecker, Brett, Nikiforow, Sarah, Ritz, Jerome, Blazar, Bruce R., Soiffer, Robert J., Antin, Joseph H., Alyea, Edwin P.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2015
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4604028/
https://ncbi.nlm.nih.gov/pubmed/26055298
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2015.05.027
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares